Eczema Breakthroughs Podcast Por Global Parents for Eczema Research (GPER) arte de portada

Eczema Breakthroughs

Eczema Breakthroughs

De: Global Parents for Eczema Research (GPER)
Escúchala gratis

Acerca de esta escucha

Interviews with the leading scientists and innovators, hosted by Global Parents for Eczema Research (GPER), a non-profit led by parents of children with eczema. Like what we're doing? Consider donating to GPER at: www.parentsforeczemaresearch.com/donate Do you enjoy this podcast? Rate it on Apple Podcasts, Google Podcasts or Spotify! Learn more about GPER and subscribe to this podcast at: parentsforeczemaresearch.orgCopyright 2025 Global Parents for Eczema Research (GPER) Ciencia Ciencias Biológicas Crianza y Familias Enfermedades Físicas Hygiene & Healthy Living Relaciones
Episodios
  • Staph’s secret superpower and their accomplice Streptococcus
    May 22 2025

    Two new studies from the Society for Investigative Dermatology (SID) conference reveal how Staph bacteria use clever strategies to disarm the skin's barrier maintenance function and work with other bacteria to amplify inflammation. Join us for an interview with Dr. Nathan Archer and Dr. Laine Feller from John Hopkins School of Medicine who explain how Staph aureus bacteria uses its superantigen superpower to hinder lipid production ... and more new research from this year's SID meeting.

    Más Menos
    14 m
  • New nonsteroidal eczema cream approved for kids
    Apr 30 2025

    New treatment alert! The FDA recently approved Tapinarof, applied as a cream, for kids 2 years and up. We ask Dr. Leon Kircik from Icahn School of Medicine, NY, who led the clinical trials about the safety, efficacy and side effects of Tapinarof. And because we are parents too, we ask: How quickly does it work? Can you start/stop it as needed? How easy will it be to access? And more. If you like our podcast, please consider supporting it with a tax deductible donation.

    Research discussed

    Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children

    Maximal usage trial of tapinarof cream 1% once daily in pediatric patients down to 2 years of age with extensive atopic dermatitis

    Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials

    Tapinarof cream in the treatment of atopic dermatitis in children and adults a systematic review and meta-analysis

    Efficacy and safety of Ruxolitinib, Crisaborole, and Tapinarof for mild-to-moderate atopic dermatitis: a Bayesian network analysis of RCTs

    Más Menos
    22 m
  • Hot off the press - What researchers are talking about at AAAAI Allergy Conference.
    Mar 20 2025

    What to look out for in eczema moisturizers, why eczema babies have rosy red cheeks and can allergies transfer to baby from breast milk? Join Korey Capozza, Dr. Jessica Hui-Beckman (National Jewish Health) and Dr. Kirsi Jarvinen-Seppo (University of Rochester) to find the answers. If you like our podcast, please consider supporting it with a tax deductible donation.

    Research discussed

    Consumer Preferences, Product Characteristics, and Potentially Allergenic Ingredients in Best-selling Moisturizers

    Early Life Cheek Skin Barrier Changes are Associated with Atopic Dermatitis Development

    Prevention of IgE-Mediated Food Allergy: Emerging Strategies Through Maternal and Neonatal Interventions


    Más Menos
    17 m
adbl_web_global_use_to_activate_T1_webcro805_stickypopup
Todas las estrellas
Más relevante  
As a 76 year old life time sufferer this info is helpful for all eczema suffers not just children. It speaks of all the experiences one has had as a sufferer and is reassuring that eczema is not just a reaction to stress and the wrong foods. It speaks to how eczema works and shows hope for the future. It’s particularly helpful in choosing treatment methods for the individual based on fact and not fiction.

Great and helpful Podcast

Se ha producido un error. Vuelve a intentarlo dentro de unos minutos.